Skip to content
    IPGP
    Earnings call· Mar 2026(Q1 FY26)

    IPG PHOTONICS Q1 FY26 earnings call IPGP

    May 5, 2026 Source

    Executive summary

    IPG Photonics Q1 FY26 — Strong Revenue Growth Driven by Battery Manufacturing and Medical

    IPG Photonics delivered a strong Q1 FY26, with revenue up 17% year-over-year, driven by robust demand in battery manufacturing and medical applications. The company introduced a new reporting framework, highlighting growth in both Industrial and Advanced Solutions. Despite macroeconomic uncertainties and tariff headwinds, strong bookings and a healthy backlog provide confidence in the outlook, with a continued focus on strategic growth initiatives and operational efficiency.

    Highlights

    5

    • First quarter revenue exceeded expectations, increasing 17% year-over-year to $265 million.

    • Industrial Solutions revenue grew 21% year-over-year, accounting for 86% of total sales.

    • Total bookings were strong with book-to-bill firmly above 1 for the second consecutive quarter.

    • Medical revenue grew significantly year-over-year, supported by a very strong backlog for 2026.

    • North American revenue increased 27% compared with last year.

    Concerns

    4

    • Advanced Solutions revenue declined modestly year-over-year and 13% quarter-over-quarter due to lower micromachining and sequential medical sales.

    • GAAP operating loss was $8 million in the quarter.

    • Tariffs are expected to persist in 2026, impacting gross margin by approximately 150 basis points.

    • Underabsorbed expenses continue to run at a higher level than targeted.

    Guidance & targets

    8
    CategoryTargetConfidence
    Revenue
    $260 million to $290 million
    high materiality
    High
    Adjusted Gross Margin
    37% and 40%
    medium materiality
    High
    Adjusted Operating Expenses
    $92 million to $95 million
    medium materiality
    High
    Adjusted Operating Expenses
    increase moderately
    low materiality
    Medium
    Adjusted EPS
    $0.25 to $0.55
    high materiality
    High
    Adjusted EBITDA
    $32 million and $48 million
    medium materiality
    High
    Capital Expenditures
    $90 million to $100 million
    medium materiality
    High
    Medical Revenue
    another good year
    medium materiality
    High

    Segment performance

    5
    SegmentRevenueYoYQoQMargin
    Industrial Solutions
    Driven by growth in welding, cutting, marking, and cleaning applications. Benefited from solid demand and new orders from battery manufacturing. Outperformed typical seasonality sequentially.
    		86% of total sales21%flat—
    Advanced Solutions
    Growth in medical and semiconductor applications was offset by lower micromachining sales due to cyclical demand in solar cell manufacturing. Sequential decline due to lower medical sales from an exceptionally strong Q4 2025.
    		14% of total salesmodestly declineddown 13%—
    North America
    Year-over-year growth driven by welding, cutting, additive manufacturing, and medical applications. Sequential decline due to lower sales in cleaning and medical, partially offset by strength in other areas.
    		—27%down 4%—
    Europe
    Year-over-year growth driven by cutting. Sequential decline due to lower sales in welding, cleaning, and additive manufacturing.
    		—4%down 13%—
    Asia
    Year-over-year growth driven by strong demand in welding, cutting, marking, and cleaning applications, primarily benefiting from capacity additions for battery manufacturing.
    		—14%flat—

    Operational metrics

    22
    Total Revenue
    $265 millionup 17% year-over-year
    Q1 FY26

    Marking the second consecutive quarter of double-digit sales growth.

    FX Benefit to Revenue
    4%compared to prior year
    Q1 FY26

    Foreign currency benefited revenue by approximately 4% this quarter compared to the same period in the prior year.

    GAAP Gross Margin
    37.5%
    Q1 FY26

    Benefited year-over-year from lower inventory provisions due to improved inventory management.

    Adjusted Gross Margin
    37.8%improved sequentially
    Q1 FY26

    Came in close to the midpoint of guidance range and improved sequentially. Experienced headwinds from tariffs compared to Q1 2025.

    GAAP Operating Expenses
    $107 million
    Q1 FY26

    Includes a $13.5 million payment and license related to an agreement with TRUMPF Laser System technique.

    Adjusted Operating Expenses
    $91 million
    Q1 FY26

    Excluding settlement payment, litigation expenses, amortization of intangibles and other acquisition-related expenses. Company continues to invest in strategic initiatives.

    GAAP Operating Loss
    $8 million
    Q1 FY26

    Reported for the quarter.

    GAAP Net Income
    $2 million
    Q1 FY26

    Reported for the quarter.

    GAAP EPS
    $0.04
    Q1 FY26

    Per diluted share.

    Adjusted Operating Income
    $9 million
    Q1 FY26

    Excluding one-time items, FX and amortization.

    Adjusted Net Income
    $13 million
    Q1 FY26

    Excluding one-time items, FX and amortization.

    Adjusted EPS
    $0.29
    Q1 FY26

    Per diluted share, came in above the midpoint of guidance range.

    Adjusted EBITDA
    $35 million
    Q1 FY26

    Came in above the midpoint of guidance range.

    Cash and investments balance
    $813 million
    Q1 FY26

    Ended the quarter with cash, cash equivalents and short-term investments.

    Long-Term Investments
    $71 million
    Q1 FY26

    Reported balance.

    Debt
    $0
    Q1 FY26

    No debt reported.

    Cash Used in Operations
    $5 million
    Q1 FY26

    The first quarter is typically weaker for cash generation due to annual bonus payments.

    Capital Expenditures
    $16 million
    Q1 FY26

    Below the expected run rate given the full-year CapEx budget, due to timing of investments in the German fiber manufacturing facility.

    Underlying Capital Expenditures
    5%
    Q1 FY26

    Excluding the German investment, underlying CapEx is running at about 5% of revenue and expected to maintain this level.

    Emerging Growth Products Revenue
    53%consistent with prior quarter
    Q1 FY26

    Many of these products are benefiting from growth in battery manufacturing and the medical market.

    Tariff Impact on Gross Margin
    150 basis points
    FY26

    Ongoing impact from tariffs expected to persist in 2026.

    Diluted Common Shares Outstanding
    43 million
    Q2 FY26

    Used for Q2 EPS guidance.

    Industry KPIs

    7
    MetricValueDetails
    Orders book to billfirmly above 1
    Segment revenue growthIndustrial Solutions: $227.9M, Advanced Solutions: $37.1MUSD
    Design wins product cycle rampsnew lithography, metrology and inspection business
    Order visibility backlog policyvery strong backlog for 2026
    Capacity expansion internal sourcing$90 million to $100 millionUSD
    End market revenue mix organic growthIndustrial Solutions: 86%, Advanced Solutions: 14%%
    Operating margin incremental leverage37.8%%

    Orderbook & backlog

    2
    Total BookingsstrongQ1 FY26

    firmly above 1 (book-to-bill)

    Book-to-bill firmly above 1 for the second consecutive quarter, giving confidence in the outlook and pointing to robust demand.

    Medical Backlogvery strongQ1 FY26

    Provides excellent visibility into full year 2026 revenue, pointing to another good year in medical.

    Product announcements

    4
    ProductTypeDetails
    Crossbowupdate
    Medical productsroadmap
    RAC integrated lasers with new cutting headsexpansion
    Cleaning systemsexpansion

    Deals & partnerships

    2
    Lockheed MartinFollow-on order for Crossbow high-energy laser defense system$10 million

    Lockheed Martin placed a $10 million follow-on order for IPG's Crossbow scalable, cost-effective, high-energy laser defense system for countering Group 1 and Group 2 drone threats.

    TRUMPF Laser System techniqueSettlement of litigation and license agreement$13.5 million

    A $13.5 million payment and license related to an agreement settling all parts of litigation between the companies worldwide.

    Capital programs

    1
    Major fiber manufacturing facility in Germanyunderway$90 million to $100 million
    Period spend: $16 million

    The full-year CapEx budget of $90 million to $100 million is due to investments in this facility. Q1 spend was $16 million, below the expected run rate due to timing of investments.

    Risks & headwinds

    5
    Elevated macroeconomic uncertainty

    not quantified

    Mitigation: Remaining cautiously optimistic in outlook; focusing on executing growth strategy, operational excellence, and innovation.

    Tariffspersist in 2026

    150 basis points impact on gross margin

    Mitigation: Working on cost reduction and pricing initiatives to offset the impact.

    Underabsorbed expensesongoing

    running at a higher level than targeted

    Mitigation: Specific initiatives underway to improve operational efficiency.

    Geopolitical developments (Middle East)

    potential influence on freight costs

    Mitigation: Limited direct exposure to petrochemicals and energy markets; vertical integration provides resilience against potential adverse impacts.

    Tougher comparisons in second half of 2026H2 FY26

    not quantified

    Mitigation: Acknowledged by management, implying a potential deceleration in growth rates compared to a strong H2 FY25.

    What to watch in Q2 FY26

    5

    Gross Margin Trajectory

    next quarter and beyond
    Current37.8% (adjusted)
    Targetmid-40s target

    Why it matters

    Management reaffirmed the long-term gross margin target despite tariff headwinds🌐, and Q2 guidance reflects momentum. Verification of continued improvement is key to profitability.

    In general, that's a target we're still striving to get to. We are starting to see some of the cost reduction initiatives and some of the pricing that we talked about last year paid through.

    Q&A highlights

    7

    Is the mid-40s gross margin target still valid given tariffs and input costs?

    Tim Mammen affirmed that the mid-40s gross margin target remains valid. He highlighted ongoing cost reduction and pricing initiatives, along with efforts to improve absorption of fixed manufacturing costs. Tariffs are acknowledged as a 150 basis point headwind, but Q2 guidance reflects positive momentum.

    “In general, that's a target we're still striving to get to. We are starting to see some of the cost reduction initiatives and some of the pricing that we talked about last year paid through.”

    asked by Ruben Roy · answered by Timothy P.V. Mammen

    2 min read5 chapters

    Detailed Narrative

    01

    New Reporting Framework for Strategic Clarity

    IPG Photonics introduced an updated revenue reporting framework, segmenting its business into Industrial Solutions (86% of Q1 revenue) and Advanced Solutions (14% of Q1 revenue). This change aims to provide clearer visibility into strategic growth initiatives by separating industrial and non-industrial revenue streams, each characterized by distinct performance and growth profiles. The company believes this new structure will enhance understanding of its market focus and progress.

    02

    Industrial Solutions Drive Strong Performance

    The Industrial Solutions segment reported a 21% year-over-year revenue increase, driven by robust demand in welding, cutting, marking, and cleaning applications. A significant contributor was battery manufacturing, spanning both electric vehicles and stationary storage, which benefits from IPG's differentiated adjustable mode beam lasers and real-time process monitoring. Sequentially, Industrial Solutions revenue remained flat, outperforming typical seasonality.

    03

    Advanced Solutions Progress in High-Growth Markets

    Advanced Solutions, targeting a $5 billion total addressable market across medical, defense, micromachining, and semiconductor manufacturing, saw growth in medical and semiconductor applications. This was partially offset by a decline in micromachining sales due to cyclical demand in solar cell manufacturing. The segment's sequential revenue decreased by 13% following an exceptionally strong Q4 2025 in medical sales, but the company remains optimistic about its long-term growth opportunities.

    04

    Defense and Medical Traction

    In defense, IPG Photonics secured a $10 million follow-on order from Lockheed Martin for its Crossbow high-energy laser defense system, with shipments commencing in Q2. The system, designed to counter drone threats, continues to generate significant customer interest. The medical segment experienced substantial year-over-year revenue growth, driven by a new customer, and boasts a strong backlog for 2026, providing excellent full-year revenue visibility.

    05

    Focus on Operational Efficiency and Margin Improvement

    Despite achieving an adjusted gross margin of 37.8% in Q1, the company is actively pursuing initiatives to improve product margins through cost reductions and pricing strategies. Tariffs remain a headwind, impacting gross margin by approximately 150 basis points, and underabsorbed expenses are higher than desired. Management is implementing specific measures to enhance operational efficiency and mitigate these pressures, aiming for a structural gross margin in the mid-40s.

    AI-generated summary of the company’s earnings call. Not investment advice.